PPARA and diabetic kidney disease: For example, fenofibrate, a PPARα agonist that is currently utilized for the treatment of hypertriglyceridemia, is currently being evaluated in a phase 3 trial for the treatment of patients with diabetic kidney disease (NCT03869931).